Floatz logo

Palbociclib

Hormone Receptor Positive Malignant Neoplasm of Breast

BeOne MedicinesSmall moleculePhase 3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hormone Receptor Positive Malignant Neoplasm of Breast cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Capecitabine
Kristina A. Fanucci
Phase 4BBB

View all 50 →

Same molecule, other indications

Palbociclib is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →